Q&A

Reducing CMC Risk From IND To Commercial Manufacturing Of Cell And Gene Therapies

Source: Cytiva

By J. Kelly Ganjei, CEO of Cognate BioServices, David Pryce, CEO of Devacel, Shailesh Maingi, Founder and Chairman of Kineticos Life Sciences, Beth Webb, Global GM for Commercial for Cell and Gene Therapy at Cytiva

iStock-1159995989-cell-gene-map

access the Q&A!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

Cytiva